Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(-)-5-hydroxypluviatolide
-
50% inhibition at 0.05 mM
(-)-epicatechin-3-gallate
(-)-epigallo-3-catechin gallate
-
-
(-)-epigallocatechin-3-gallate
-
inhibitory effect is increased on presence of 10 mM CaCl2, no interaction with Cl-
(-)-gallocatechin-3-gallate
(-)-haplomyrfolin
-
50% inhibition at 0.1 mM
(-)-hinokinin
-
50% inhibition at 0.1 mM
(-)-thujaplicatin-d3
-
50% inhibition at 0.08 mM
(4-phenyl-1,4-dihydropyridine-3,5-diyl)dimethanol
-
1-(4-methoxyphenyl)sulfonyl-4-(tert-butoxycarbonyl)-piperazine-2-carboxylic acid
-
-
3,9-di(4-methoxylphenyl)-6,12-diphenyl-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
3,9-di(4-methylphenyl)-6,12-diphenyl-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
3,9-dibenzyl-1,5,7,11-tetrahydroxymethyl-6,12-di(2,3,4-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane
-
3,9-dibenzyl-1,5,7,11-tetrahydroxymethyl-6,12-di(2,4,5-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane
-
3,9-dibenzyl-1,5,7,11-tetrahydroxymethyl-6,12-di(2,4-dimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane
-
3,9-dibenzyl-1,5,7,11-tetrahydroxymethyl-6,12-di(4-hydroxyphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane
-
3,9-dibenzyl-6,12-di(2,3,4-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
3,9-dibenzyl-6,12-di(2,4,5-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
3,9-dibenzyl-6,12-di(2,4-dimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
3,9-dibenzyl-6,12-di(3,4,5-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
3,9-dibenzyl-6,12-di(4-hydroxyphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
3,9-dibenzyl-6,12-di(4-methoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
3,9-dibenzyl-6,12-diphenyl-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
3,9-diphenyl-6,12-di(4-fluoridephenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
3,9-diphenyl-6,12-di(4-hydroxyphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
3,9-diphenyl-6,12-di(4-methoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
3,9-diphenyl-6,12-di(4-methylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
3,9-diphenyl-6,12-diphenyl-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
3.9-diphenyl-6,12-di(3,4,5-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
6,12-di(2,3,4-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
6,12-di(2,4,5-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
6,12-di(2,4-dimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
6,12-di(3,4,5-trimethoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
6,12-di(4-hydroxyphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
6,12-di(4-methoxylphenyl)-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
6,12-diphenyl-3,9-diazahexacyclo[6.4.0.02,7.04,11.05,10]dodecane-1,5,7,11-tetracarboxylate
-
andrographolide
-
a diterpenoid lactone isolated from a traditional herbal medicine Andrographis paniculata, downregulates MMP-7 in colorectal carcinoma LoVo cells leading to inhibition of cell migration and invasion, overview
BB-94
-
[4-(N-hydroxyamino)-(2R)-isobutyl-(3S)-(thienylthiomethyl)-succinyl]-L-Phe-N-methylamine
Brij-35
activates MMP-7 in a broad concentration range, but inhibits at high concentration
cardiolipin
associates with the enzyme at the cell surface and inhibits by 92%
diethyl 1-phenoxy-4-(4-propylphenyl)-1,4-dihydropyridine-3,5-dicarboxylate
-
diethyl 4-(2-methoxyphenyl)-1,4-dihydropyridine-3,5-dicarboxylate
-
diethyl 4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
-
diethyl 4-(3-methoxyphenyl)-1,4-dihydropyridine-3,5-dicarboxylate
-
diethyl 4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
-
diethyl 4-(4-methylphenyl)-1,4-dihydropyridine-3,5-dicarboxylate
-
diethyl 4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
-
diethyl 4-(4-nitrophenyl)-1-phenoxy-1,4-dihydropyridine-3,5-dicarboxylate
-
diethyl 4-(4-propylphenyl)-1,4-dihydropyridine-3,5-dicarboxylate
-
diethyl 4-[4-(5-methoxypentyl)phenyl]-1,4-dihydropyridine-3,5-dicarboxylate
-
diethyl 4-[4-(5-methoxypentyl)phenyl]-1-phenoxy-1,4-dihydropyridine-3,5-dicarboxylate
-
dimethyl sulfoxide
-
competitive inhibition
fibronectin 1
-
fibronectin 1, interacts with MMP-7
-
methyl 1-(4-methoxyphenyl)sulfonyl-4-(N-methyl-N-hexylaminocarbonyl)piperazine-2-carboxylate
-
-
methyl 1-(4-methoxyphenyl)sulfonyl-4-(tert-butoxycarbonyl)piperazine-2-carboxylate
-
-
methyl 1-(4-methoxyphenyl)sulfonyl-4-acetylpiperazine-2-carboxylate
-
-
methyl 1-(4-methoxyphenyl)sulfonyl-4-amidopiperazine-2-carboxylate
-
-
methyl 1-(4-methoxyphenyl)sulfonyl-4-cyclohexanecarbonylpiperazine-2-carboxylate
-
-
methyl 1-(4-methoxyphenyl)sulfonyl-4-methylpiperazine-2-carboxylate
-
-
methyl 1-(4-methoxyphenyl)sulfonyl-4-methylsulfonylpiperazine-2-carboxylate
-
-
methyl 1-(4-methoxyphenyl)sulfonylpiperazine-2-carboxylate hydrochloride
-
-
methyl 4-[4-(4-bromophenyl)thiazol-2-yl]-1-(4-methoxyphenyl)sulfonylpiperazine-2-carboxylate
-
-
methyl-beta-cyclodextrin
inhibits release of the HAI-1 fragment by MMP-7-catalyzed cleavage
MMPI-II
a small synthetic inhibitor of 514 Da
N-hydroxy-1,4-bis(4-methoxyphenylsulfonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-bromophenyl)sulfonyl-4-(N-methyl-N-hexylaminocarbonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-bromophenyl)sulfonyl-4-(S)-(2-hydroxy-3-methyl-1-oxobutyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-bromophenyl)sulfonyl-4-[N-bis(2-methoxyethyl)aminocarbonyl]piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(1-oxohexyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(2-phenylethylaminocarbonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(3-ethoxy-1-propoxycarbonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(3-methoxyphenylaminocarbonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(3-pyridinylmethoxycarbonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(4-biphenylcarbonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(4-methyl-1,2,3-thiadiazole-5-carbonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(4-morpholinylcarbonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(5-methyl-3-phenylisoxazole-4-carbonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(isoxazole-5-carbonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(n-hexyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(n-hexylaminocarbonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(N-methyl-N-hexylaminocarbonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(N-methyl-N-phenylmethylaminocarbonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(N-methylpiperazine-1N-carbonyl)piperazine-2-carboxamide hydrochloride
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(N-propyl-N-cyclopropylmethyl aminocarbonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-(tert-butoxycarbonyl)piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-acetylpiperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-amidopiperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-benzoylpiperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-benzylcarbamoylpiperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-benzyloxycarbonylpiperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-benzylthiocarbamoylpiperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-cyclohexanecarbonylpiperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-furoylpiperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-methylpiperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-nicotinoylpiperazine-2-carboxamide hydrochloride
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-phenoxyacetylpiperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-phenylmethylpiperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-thiophenecarbonylpiperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-[(hexahydro-1H-azepin-1-yl)carbonyl]piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonyl-4-[2-amino-4-methyl-5-thiazolylsulfonyl]piperazine-2-carboxamide
-
-
N-hydroxy-1-(4-methoxyphenyl)sulfonylpiperazine-2-carboxamide
-
-
N-hydroxy-4-[4-(4-bromophenyl)thiazol-2-yl]-1-(4-methoxyphenyl)sulfonylpiperazine-2-carboxamide
-
-
N-[3-[3,5-bis(hydroxymethyl)-1,4-dihydropyridin-4-yl]phenyl]acetamide
-
N-[3-[3,5-bis(hydroxymethyl)-1-phenoxy-1,4-dihydropyridin-4-yl]phenyl]acetamide
-
N-{(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-(naphthalen-2-yl)-L-alanyl-N-(2-aminoethyl)-L-alaninamide
-
i.e. TAPI-1, a hydroxamate-based metalloproteinase inhibitor
Pseudopeptide inhibitors
-
-
-
Sulfatide
associates with the enzyme at the cell surface and inhibits by 80%
sulindac
-
in sulindac-treated ApcMin/+ mice, a genetic model of human familial adenomatous polyposis, collagen genes, viz. Col1a2, Col5a2, Col6a2, and Col6a3, are upregulated, and matrilysin matrix metalloproteases-7 is downregulated. Mmp7 is found in hot spot areas within the tumors of ApcMin/+ mice treated with the vehicle, but is greatly diminished in those mice treated with sulindac
TAPI-1
a hydroxamate-based matrix metalloproteinase inhibitor, reduces the affinity of the enzyme for cholesterol sulfate and cardiolipin, but not for sulfatide, molecular mechanism by which TAPI-1 inhibits binding of MMP-7 to the lipids, overview
TIMP-4
-
tissue inhibitor of metalloproteinases-4
-
TIMP3
-
tissue inhibitor of metalloproteinase-3, interacts with MMP-7
-
tissue inhibitor of metalloproteinase
i.e. TIMP-1. TIMP-1 and matrilysin co-localize and co-immunoprecipitate in wounded primary airway epithelial cultures. TIMP-1-deficient cultures migrate faster, and epithelial cells spread to a greater extent compared with wild-type cultures. TIMP-1 also inhibits matrilysin-mediated cell migration and spreading in vitro. In vivo, TIMP-1 deficiency enhances airway re-epithelialization after naphthalene injury. TIMP-1 and matrilysin co-localize in airway epithelial cells adjacent to the wound edge
-
Tissue inhibitor of metalloproteinase-1
-
-
-
tissue inhibitors of metalloproteinase 1
TIMP-1
-
[(2'R,3'S)-2'-iso-butyl-3'-hydroxy-4'-nitro]butyryl-(S)-tert-leucyl-[(1'',1'')-diphenyl]-methylamide
-
[(2'R,3'S)-2'-iso-butyl-3'-hydroxy-4'-nitro]butyryl-(S)-tert-leucyl-[(1''R)-phenyl]-ethylamide
-
[(2'R,3'S)-2'-iso-butyl-3'-hydroxy-4'-nitro]butyryl-(S)-tert-leucyl-[(1''S)-phenyl]-ethylamide
-
[(2'R,3'S)-2'-iso-butyl-3'-hydroxy-4'-nitro]butyryl-(S)-tert-leucylmethylamide
-
[(2'R,3'S)-2'-iso-butyl-3'-hydroxy-4'-nitro]butyryl-(S)-tert-leucylphenylamide
-
[4-(2,4-dimethoxyphenyl)-1-phenoxy-1,4-dihydropyridine-3,5-diyl]dimethanol
-
[4-(3,4,5-trimethoxyphenyl)-1,4-dihydropyridine-3,5-diyl]dimethanol
-
[4-(4-methoxyphenyl)-1,4-dihydropyridine-3,5-diyl]dimethanol
-
[4-(4-nitrophenyl)-1,4-dihydropyridine-3,5-diyl]dimethanol
-
[4-(4-propylphenyl)-1,4-dihydropyridine-3,5-diyl]dimethanol
-
(-)-catechin-3-gallate
-
-
(-)-catechin-3-gallate
-
inhibition is un affected by presence of 10 mM CaCl2
(-)-epicatechin-3-gallate
-
-
(-)-epicatechin-3-gallate
-
inhibition is un affected by presence of 10 mM CaCl2
(-)-gallocatechin-3-gallate
-
-
(-)-gallocatechin-3-gallate
-
inhibitory effect is increased on presence of 10 mM CaCl2, no interaction with Cl-
1,10-phenanthroline
-
-
batimastat
-
i.e. BB-94, BB-94 significantly reduces the amount of N-cadherin fragment produced in response to Fas-L
Cholesterol sulfate
non-competitive inhibition, decreases the enzyme's thermostability, inhibition mechanism, overview
Cholesterol sulfate
associates with the enzyme st the cell surface and modulates the substrate preference of the enzyme, 20% inhibition
EDTA
-
-
EDTA
inhibits MMP-7-induced cell aggregation
GM6001
-
GM6001
-
a broad-spectrum MMP inhibitor
Hydroxamate
-
-
TIMP-1
i.e. type 1 tissue inhibitor of MMPs, is elevated in colorectal tumor tissue compared to healthy mucosa
-
TIMP-1
expression and activity of MMP-7 in fetal membranes during premature rupture of membranes is increased, while the TIMP-1 level is reduced, immunohistochemic analysis, overview
-
TIMP-1
-
tissue inhibitor of metalloprotease-1
-
TIMP-1
-
no apparent regulation of the expression of TIMP-1 by either tumor necrosis factor or enamel matrix derivative
-
TIMP-1
-
from gingival and dermal fibroblasts forms complexes with MMP-7 and inhibits its expression and activity
-
TIMP-3
-
tissue inhibitor of metalloproteinases-3
-
TIMP-3
-
is induced by enamel matrix derivative
-
additional information
-
examination of inhibitor-enzyme complexes emphasizes the dominant role the zinc-coordination group plays in determining the relative potencies of their inhibitors
-
additional information
-
no inhibition with phosphoramidon
-
additional information
-
for lignans, dibenzylbutyryrolactone structure is essential for inhibitory effect
-
additional information
estrogen acidification of the luminal solution tends to alkalinize exocytotic vesicles and may lead to decreased activation of the MMP-7
-
additional information
-
estrogen acidification of the luminal solution tends to alkalinize exocytotic vesicles and may lead to decreased activation of the MMP-7
-
additional information
MMP-7 interacts with anionic, cationic and neutral lipid membranes, while the catalytic activity of the enzyme remains unaffected upon binding to neutral and negatively charged membranes, it is drastically impaired upon binding to the positively charged membranes, overview
-
additional information
angiogenesis and apoptosis do not influence MMP-7 expression in lung cancer cells, overview
-
additional information
-
angiogenesis and apoptosis do not influence MMP-7 expression in lung cancer cells, overview
-
additional information
inhibition of hyaluronan synthases HAS2 and HAS3 highly decreases MMP-7 expression and activity in SW620 cells
-
additional information
-
MMP-7 knockout or inhibition retards cleavage of N-cadherin and vascular smooth muscle cell apoptosis, overview
-
additional information
-
green tea catechins inhibit MMP-7 competitively and the galloyl group is essential, differences result from the B-ring, mechanism of inhibition
-
additional information
design, synthesis and biological evaluation of 3,9-diazatetraasteranes as matrilysin inhibitors, molceular docking and simulations, overview. Common interaction mechanism of 3,9-diazatetraasteranes with the catalytic site of matrilysin
-
additional information
the internal four residues Ile29, Arg33, Arg51 and Trp55 of MMP-7 are important for binding of inhibitory acidic lipids, overview
-
additional information
nitro-based selective inhibitors against matrix metalloproteinase-7, overview. Kinetics and active-site-binding mode of the inhibitors, molecular docking. A reasonable adjustment of the P'3 side chains of the nitro-based MMP inhibitors could improve selectivity for the inhibition of MMP-7 over MMP-1 (EC 3.4.24.7)
-
additional information
the enzyme contains an auto-inhibitory peptide
-
additional information
-
two zinc and two calciums are required for inhibitor binding
-
additional information
-
MMP-7 knockout or inhibition retards cleavage of N-cadherin and vascular smooth muscle cell apoptosis, overview
-
additional information
-
not: phosphoramidon; Zincov
-